Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.

Autor: Ishizuka, Osamu, Nishizawa, Osamu, Nishizawa, Shuji, Satoh, Tomoya, Wajiki, Masahisa, Kiyokawa, Hideo, Inoue, Yoshihiro, Kobayashi, Shinya, Mizusawa, Hiroya, Nakagawa, Tatsuo
Předmět:
Zdroj: International Journal of Clinical Oncology; Jun2013, Vol. 18 Issue 3, p524-530, 7p
Abstrakt: Background: We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Methods: Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Results: Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively ( P = 0.798). At each week, the levels in both groups were ≤0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively ( P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. Conclusions: There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: